← Back to list
MA08.094c, Voretigene Neparvovec-rzyl (Luxturna®)
Effective date
Not stated in the notice
Identified
Jun 19, 2026
Summary
This is a reissue with no substantive changes to MA08.094c covering voretigene neparvovec-rzyl (Luxturna®) for RPE65-associated retinal dystrophy. The policy was reissued on 04/01/2026 as part of the annual review process, confirming Independence Blue Cross's continuing coverage position. No billing codes, coverage criteria, or medical necessity requirements have been modified.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
Action · 4 steps
01No immediate action required.
02Billing team should note this is a reissue with no changes.
03Verify that current billing system reflects the existing HCPCS code J3398 for voretigene neparvovec-rzyl injection and that prior authorization processes continue to align with documented medical necessity criteria (biallelic RPE65 variation confirmation, viable retinal cells, age 3-<65 years, certified treatment center administration, baseline FST testing, and exclusion criteria review).
04No system updates needed unless previously implemented for this drug therapy.
Codes mentioned
J3398
Original notice
MA08.094c, Voretigene Neparvovec-rzyl (Luxturna®)
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →MA08.094c, Voretigene Neparvovec-rzyl (Luxturna®)LowNo effective date · Pharmacy08.01.44c, Voretigene Neparvovec-rzyl (Luxturna®)LowNo effective date · Pharmacy08.01.44c, Voretigene Neparvovec-rzyl (Luxturna®)LowNo effective date · PharmacyBrowse every Independence Blue Cross change in the policy list